SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

25 Jul 2023 Evaluate
The company's total revenue for the quarter ended June 2023 saw a slight change in the total revenue, having registered a total revenue of Rs. 4228.80 millions.The Net Profit of the company slipped to Rs. 259.40 millions from Rs. 384.70 millions, a decline of -32.57% on QoQ basis.Operating Profit reported a sharp decline to 633.20 millions from 724.30 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 4228.80 4079.00 3.67 4228.80 4079.00 3.67 16666.90 15397.20 8.25
Other Income 4.10 11.30 -63.72 4.10 11.30 -63.72 23.30 23.20 0.43
PBIDT 633.20 724.30 -12.58 633.20 724.30 -12.58 2872.20 3293.20 -12.78
Interest 77.80 41.30 88.38 77.80 41.30 88.38 250.30 141.40 77.02
PBDT 555.40 683.00 -18.68 555.40 683.00 -18.68 2621.90 3151.80 -16.81
Depreciation 198.70 201.00 -1.14 198.70 201.00 -1.14 706.00 789.50 -10.58
PBT 356.70 482.00 -26.00 356.70 482.00 -26.00 1915.90 2362.30 -18.90
TAX 97.30 97.30 0.00 97.30 97.30 0.00 502.30 817.10 -38.53
Deferred Tax 11.80 -56.70 -120.81 11.80 -56.70 -120.81 -49.70 -73.40 -32.29
PAT 259.40 384.70 -32.57 259.40 384.70 -32.57 1413.60 1545.20 -8.52
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 14.97 17.76 -15.67 14.97 17.76 -15.67 17.23 21.39 -19.43

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×